FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367302777> ?p ?o ?g. }

• W4367302777 abstract "<h3>Objective:</h3> Evaluation for B-cell abnormalities in breastfed infants of mothers with multiple sclerosis (MS) who are on anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab). <h3>Background:</h3> Patients with MS are at high risk of relapses in the postpartum period. Breastfeeding has been demonstrated to have some protective effect against postpartum relapses. However, data in regard to safety of most MS disease modifying therapies in breastfeeding is poorly established, leading to a decision between either early reinitiation of DMT postpartum versus breastfeeding. <h3>Design/Methods:</h3> We retrospectively evaluated 7 patients in our practice at the Rocky Mountain MS Center at the University of Colorado who had breastfed their infants on anti-CD20 therapies. These infants had a CBC and B-cell panel checked through their pediatricians as standard of care after treatment with anti-CD20 postpartum. <h3>Results:</h3> In all seven of these infants, there were no abnormalities found in either their CD19 or CD20 cell counts. The average age of the mothers with MS was 35.4 years. Typically, B-cell depleting agents were resumed between 1–6 months postpartum. The B-cell panels were checked between 2–12 weeks after their mother had received their infusion (rituximab, ocrelizumab) or 2 weeks after an injection (ofatumumab). <h3>Conclusions:</h3> In our small retrospective case series, we do not identify any B-cell abnormalities in breastfed infants whose mothers are receiving anti CD20 therapies early in the postpartum period for treatment of multiple sclerosis. Additional patients will likely be added to this case series before presentation as well as further details about the subjects. This data provides additional safety information to this treatment strategy for the infant while maintaining the mother with highly effective immunotherapy treatments for multiple sclerosis. <b>Disclosure:</b> The institution of Dr. Shah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. The institution of Dr. Shah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Shah has received personal compensation in the range of $5,000-$9,999 for serving as a Educational Speaker with Rocky Mountain MS Center. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alvarez has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of an immediate family member of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB." @default.
• W4367302777 created "2023-04-29" @default.
• W4367302777 creator A5008676528 @default.
• W4367302777 creator A5064205043 @default.
• W4367302777 date "2023-04-25" @default.
• W4367302777 modified "2023-10-18" @default.
• W4367302777 title "Evaluation of B-cell Abnormalities in Infants of Breastfeeding Mothers on anti-CD20 Therapies for Multiple Sclerosis (S31.001)" @default.
• W4367302777 doi "https://doi.org/10.1212/wnl.0000000000204239" @default.
• W4367302777 hasPublicationYear "2023" @default.
• W4367302777 type Work @default.
• W4367302777 citedByCount "0" @default.
• W4367302777 crossrefType "proceedings-article" @default.
• W4367302777 hasAuthorship W4367302777A5008676528 @default.
• W4367302777 hasAuthorship W4367302777A5064205043 @default.
• W4367302777 hasConcept C126322002 @default.
• W4367302777 hasConcept C18031839 @default.
• W4367302777 hasConcept C185592680 @default.
• W4367302777 hasConcept C187212893 @default.
• W4367302777 hasConcept C203014093 @default.
• W4367302777 hasConcept C2775871700 @default.
• W4367302777 hasConcept C2776283161 @default.
• W4367302777 hasConcept C2778714382 @default.
• W4367302777 hasConcept C2778843634 @default.
• W4367302777 hasConcept C2779234561 @default.
• W4367302777 hasConcept C2779338263 @default.
• W4367302777 hasConcept C2780640218 @default.
• W4367302777 hasConcept C2780653079 @default.
• W4367302777 hasConcept C3018745865 @default.
• W4367302777 hasConcept C54355233 @default.
• W4367302777 hasConcept C55493867 @default.
• W4367302777 hasConcept C71924100 @default.
• W4367302777 hasConcept C86803240 @default.
• W4367302777 hasConceptScore W4367302777C126322002 @default.
• W4367302777 hasConceptScore W4367302777C18031839 @default.
• W4367302777 hasConceptScore W4367302777C185592680 @default.
• W4367302777 hasConceptScore W4367302777C187212893 @default.
• W4367302777 hasConceptScore W4367302777C203014093 @default.
• W4367302777 hasConceptScore W4367302777C2775871700 @default.
• W4367302777 hasConceptScore W4367302777C2776283161 @default.
• W4367302777 hasConceptScore W4367302777C2778714382 @default.
• W4367302777 hasConceptScore W4367302777C2778843634 @default.
• W4367302777 hasConceptScore W4367302777C2779234561 @default.
• W4367302777 hasConceptScore W4367302777C2779338263 @default.
• W4367302777 hasConceptScore W4367302777C2780640218 @default.
• W4367302777 hasConceptScore W4367302777C2780653079 @default.
• W4367302777 hasConceptScore W4367302777C3018745865 @default.
• W4367302777 hasConceptScore W4367302777C54355233 @default.
• W4367302777 hasConceptScore W4367302777C55493867 @default.
• W4367302777 hasConceptScore W4367302777C71924100 @default.
• W4367302777 hasConceptScore W4367302777C86803240 @default.
• W4367302777 hasLocation W43673027771 @default.
• W4367302777 hasOpenAccess W4367302777 @default.
• W4367302777 hasPrimaryLocation W43673027771 @default.
• W4367302777 hasRelatedWork W2272446420 @default.
• W4367302777 hasRelatedWork W2492099929 @default.
• W4367302777 hasRelatedWork W2511874056 @default.
• W4367302777 hasRelatedWork W2768964978 @default.
• W4367302777 hasRelatedWork W2908850704 @default.
• W4367302777 hasRelatedWork W2971869275 @default.
• W4367302777 hasRelatedWork W3206160011 @default.
• W4367302777 hasRelatedWork W4285384838 @default.
• W4367302777 hasRelatedWork W4312925133 @default.
• W4367302777 hasRelatedWork W4360619161 @default.
• W4367302777 isParatext "false" @default.
• W4367302777 isRetracted "false" @default.
• W4367302777 workType "article" @default.